Quote | Pyxis Oncology Inc. (NASDAQ:PYXS)
Last: | $2.94 |
---|---|
Change Percent: | 0.63% |
Open: | $3.18 |
Close: | $2.94 |
High: | $3.18 |
Low: | $2.92 |
Volume: | 892,879 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Pyxis Oncology Inc. (NASDAQ:PYXS)
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
2024-06-10 05:54:47 ET Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in...
Message Board Posts | Pyxis Oncology Inc. (NASDAQ:PYXS)
Subject | By | Source | When |
---|---|---|---|
I did, nice P&D | TheFinalCD | investorshub | 04/10/2023 12:15:10 AM |
Wouldn't touch it until we see if that | SpaceTimeRift777 | investorshub | 04/05/2023 12:40:01 PM |
Perfect example of dilution,in other words a classic | spencer22 | investorshub | 04/04/2023 11:19:03 AM |
7). https://finviz.com/quote.ashx?t=$PYXS&p=d$10.75 PYX | 0210 | investorshub | 03/31/2023 9:23:02 PM |
buyin' dips $4.00 - $4.10. https://ih.advfn.com/stock-market/NASDAQ/pyxis-oncology-$PYXS/tr | 0210 | investorshub | 03/31/2023 8:42:02 PM |
News, Short Squeeze, Breakout and More Instantly...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...